Bolt Biotherapeutics (NASDAQ:BOLT) & Radiopharm Theranostics (NASDAQ:RADX) Head-To-Head Comparison

Radiopharm Theranostics (NASDAQ:RADX) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Profitability

This table compares Radiopharm Theranostics and Bolt Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Bolt Biotherapeutics	N/A	-94.22%	-50.56%

Insider and Institutional Ownership

86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 6.1% of Bolt Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Radiopharm Theranostics and Bolt Biotherapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$2.35 million	24.98	-$24.83 million	N/A	N/A
Bolt Biotherapeutics	$7.69 million	1.44	-$63.12 million	($22.38)	-0.26

Radiopharm Theranostics has higher earnings, but lower revenue than Bolt Biotherapeutics.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Radiopharm Theranostics and Bolt Biotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1	0	2	2	3.00
Bolt Biotherapeutics	1	2	2	0	2.20

Radiopharm Theranostics currently has a consensus target price of $15.33, suggesting a potential upside of 208.52%. Bolt Biotherapeutics has a consensus target price of $34.00, suggesting a potential upside of 489.25%. Given Bolt Biotherapeutics’ higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Radiopharm Theranostics.

Summary

Radiopharm Theranostics beats Bolt Biotherapeutics on 6 of the 10 factors compared between the two stocks.

About Radiopharm Theranostics

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.